Role of the TWEAK-Fn14-cIAP1-NF-κB signaling axis in the regulation of myogenesis and muscle homeostasis

Emeka K. Enwere, Eric C. LaCasse, Nadine J. Adam and Robert G. Korneluk

INTRODUCTION

Skeletal muscle is comprised of multinucleated fibers that result from the fusion of hundreds or thousands of individual mononucleated progenitor cells. In addition to their highly specialized roles in the generation of force, individual muscle fibers are capable of extensive metabolic and functional plasticity. Skeletal muscle also exhibits robust regenerative capacity, as a means to recover from injury as well as to adapt to changing physical demands (1). A population of muscle-resident stem cells, known as satellite cells, resides within the laminin sheath encasing each muscle fiber, and is responsible for regeneration of muscle in the adult. These normally quiescent cells enter the cell cycle upon muscle injury, producing a transient and rapidly expanding population of committed progenitors or myoblasts. After several rounds of proliferation, the myoblasts enter a highly orchestrated differentiation program, wherein most exit the cell cycle, adopt biochemical and physiological characteristics of mature muscle, and fuse with each other to replace or repair the damaged tissue (Figure 1). The multiple steps in the process of muscle regeneration, beginning with satellite cell activation and ending with myoblast fusion, are all subject to separate levels of regulation, and are affected by a variety of muscle disorders and myopathies.

Investigation of the intracellular signaling pathways involved in muscle repair has been traditionally hampered by difficulties in accurately modeling the regenerative context in vitro. Recent developments in genetic and imaging techniques, however, have allowed new and detailed insights into many aspects of the repair process. These insights can be summarized under three major themes. First, myogenesis is comprised of several processes with distinct, and not necessarily complementary, regulatory, and signaling requirements. For instance, a pathway that promotes myoblast proliferation may have different and even inhibitory effects on the subsequent steps of myoblast differentiation, fusion, and muscle growth. Second, several cell populations co-exist with satellite cells in skeletal muscle; these other cells are either myogenic precursors [as in the case of pericytes surrounding blood vessels (2)] or non-myogenic contributors to the regenerative process, such as macrophages. Third, skeletal muscle engages in active signaling interplay with other tissue systems to maintain physiological homeostasis. Evidence in recent years has implicated the TWEAK-NF-κB signaling axis in several important functions associated with muscle damage and repair. This short review highlights both known and putative roles of TWEAK signaling in muscle biology. We emphasize recent discoveries that reflect the diverse and highly context-dependent effects of TWEAK on muscle regeneration and homeostasis. A companion article in this research topic by Sato et al. further discusses the critical importance of TWEAK signaling in skeletal muscle atrophy (3).
FIGURE 1 | Mammalian skeletal myogenesis. Upon muscle injury, a resident population of quiescent myogenic precursor cells, known as satellite cells (because they encircle muscle fibers), start to proliferate and differentiate into myoblasts. These mononuclear cells proliferate and fuse together (primary fusion step) to create multinucleated myocytes or myotubes over the course of several days. Additional myoblasts fuse to the existing myotubes in the secondary fusion step to produce even larger myotubes which eventually align to form muscle fibers. This differentiation process is regulated by many internal and external factors. Over the course of myogenesis, expression of stem cell markers such as Pax7 is gradually lost, while the appearance of differentiation markers, such as myosin heavy chain (MyHC), muscle-regulatory factor 4 (Mrf4), and muscle creatine kinase (MCK) gradually increases. The NF-κB pathways are now known to play significant roles in this differentiation process. The canonical (or classical) NF-κB pathway is needed for myogenic cell proliferation. However, upon the loss of canonical NF-κB signaling and the activation of non-canonical (or alternative) NF-κB signaling, myoblasts stop dividing and start fusing to form multinucleated myotubes, a key event in myogenesis.

REGULATION OF NF-κB SIGNALING BY TWEAK

Fibroblast growth factor-inducible protein 14 (Fn14/TNFRSF12A) is classified as a member of the tumor necrosis factor receptor (TNFR) superfamily based on its ability to bind TWEAK (TNFSF12), although it bears minimal sequence homology to other TNFR superfamily members (4, 5). Fn14 is also the smallest member of the TNFR superfamily; the proteolytically processed form that is present as a transmembrane receptor has only 102 amino acids (4, 6). Furthermore, the cytoplasmic tail contains a single TNF receptor-associated factor (TRAF)-binding domain but lacks a death domain motif normally found in several other TNFR superfamily members. The adaptor proteins TRAF-1, -2, -3, and -5 are able to bind to this site, and are essential for downstream pathway activation (5, 7, 8). Given the lack of other functional domains it is likely that all TWEAK–Fn14 signal transduction is due to interaction of Fn14 with one or more of these TRAF adaptors (9). While a comprehensive screen of TNF superfamily cytokines identified TWEAK as the only ligand able to interact with Fn14 (10), a number of reports suggests that the TWEAK–Fn14 pairing is not exclusive. For example, the scavenger receptor CD163 can bind and internalize TWEAK, though there is no evidence of signal transduction activity resulting from this interaction (11). A 2003 study (12) demonstrated the ability of TWEAK to induce robust differentiation of RAW264.7 murine macrophages, which do not express Fn14 (12, 13). Other studies have demonstrated the ability of Fn14 to activate canonical NF-κB signaling in the absence of TWEAK (7, 14). Furthermore, three separate studies reported that down-regulation of Fn14 severely attenuates myoblast fusion, even in the absence of TWEAK (15–17). Nevertheless, the interaction of TWEAK with Fn14 is sufficient to activate canonical and non-canonical NF-κB pathways (9, 18, 19), so we will focus hereafter on signaling mediated by the binding of TWEAK to Fn14.

TWEAK, THE cIAP PROTEINS, AND CANONICAL NF-κB SIGNALING

The NF-κB family consists of five transcription factor subunits, as well as a plethora of inhibitors, activators, and signal transduction molecules that function as both pathway regulators and mediators of inter-pathway cross-talk. The NF-κB subunits are RelA/p65, RelB, c-Rel, p105/p50 (NF-κB1), and p100/p52 (NF-κB2) (20). All subunits contain a Rel-homology domain near their N-termini, which confers protein dimerization and DNA-binding capabilities; however, only RelA, RelB, and c-Rel contain C-terminal transactivating domains. An NF-κB complex consists of a homodimer or heterodimer of any pair of subunits. These dimers are normally retained in the cytoplasm in an inactive state by an array of inhibitor of κB (IκB) repressor proteins. One of the better-studied NF-κB signaling axes, known as the classical or canonical pathway, principally involves signal transduction through the p50:RelA heterodimer. Upon pathway stimulation by ligands such as TNFα...
(Figure 2), a signaling complex forms, which leads to the activation of IκB kinase α, β, and NEMO complex (IKK). IKK catalyzes the phosphorylation and subsequent degradation of IκBα, thus allowing nuclear translocation of p50:RelA and transcriptional activation of NF-κB target genes.

Several studies over the past two decades have identified the cellular inhibitor of apoptosis 1 and 2 (cIAP1/2) proteins as regulators of multiple signal transduction pathways, including NF-κB, that are activated by TNF superfamily cytokines (19, 21–29). The inhibitors of apoptosis (IAP) were identified based on their homology to viral IAPs (30–32), and contain one or more N-terminal baculoviral IAP repeat (BIR) homology domains. In addition, cIAP1/2 were independently identified based on their association with the TNF receptor 2 (TNF-R2) and the adaptors TRAF1 and TRAF2 (21). These two IAPs are recruited to the various TNF superfamily receptors through direct interaction with TRAF1, TRAF2, or TRAF6 (19, 33–36). The cIAP1/2 proteins contain single C-terminal RING E3 ubiquitin ligase moieties (37), as well as ubiquitin-binding UBA domains (38), whose functions have been the focus of considerable research interest. In most cells, cIAP1 triggers the constitutive lysine-48 (K48)-ubiquitination and degradation of cIAP2 (39); thus, cIAP2 expression is low in most non-lymphoid tissues unless cIAP1 is absent, or unless cIAP2 expression is induced (40–42). Nevertheless, in many scenarios cIAP1 and cIAP2 function redundantly (28). In the context of NF-κB signaling induced by a prototypical ligand such as TNFα, the TNF receptor 1 (TNF-R1) recruits a signal transduction complex consisting of TNF-R1-associated DEATH domain (TRADD), the kinase/scaffold protein receptor-interacting protein 1 (RIP1), and TRAF2. TRAF2 recruits cIAP1/2, which in turn catalyze the polyubiquitination of RIP1 by K63- and K1-mediated linkages (43). The K63- and K11-linked chains on RIP1 serve as scaffolds for the assembly of an IKK complex consisting of TAB1, TAK1, NEMO, and IKKα,β. This complex phosphorylates IκBα, thus completing the signal transduction process upstream of the NF-κB transcription factors (Figure 2). When cIAP1/2 are depleted, either by genetic or pharmacological means (such as through the use of IAP antagonists known as SMAC mimetic compounds or SMGs), RIP1 instead activates a pro-apoptotic complex, referred to as the riposome. This complex consists of de-ubiquitinated RIP1, the DEATH domain-containing adaptor protein FADD, and caspase-8 (44, 45) (Figure 2).

The receptor Fn14 is an effector of signaling through its ability to recruit TRAF-1, -2, -3, and -5. At sufficiently high concentrations, soluble TWEAK triggers IκB phosphorylation and degradation, as well as p65 phosphorylation and nuclear translocation, events that are typical of the canonical NF-κB pathway activation (7). As Fn14 lacks a death domain, it is unable to directly recruit a death-signaling complex. Instead, apoptosis results from the phosphorylation and subsequent degradation of IκBα, thus allowing nuclear translocation of p50:RelA and transcriptional activation of NF-κB target genes.

Noncanonical NF-κB regulation of myogenesis

Transcriptional activity in the non-canonical NF-κB pathway is mediated by the p52:RelB heterodimer. This signaling axis is tightly regulated by the controlled processing of p100 into p52. Under basal conditions, a ubiquitin ligase complex consisting of TRAF2, TRAF3, and cIAP1/2 catalyzes the constitutive K48-ubiquitination and consequent degradation of the NF-κB inducing kinase (NIK), which is essential for activation of the non-canonical pathway (33, 57). Upon non-canonical NF-κB stimulation by a variety of ligands [including TWEAK, BAFF, CD40 ligand (CD40L), and RANKL], TRAF2, TRAF3, and cIAP1/2 are sequestered to the corresponding membrane-bound TNF superfamily receptor. Here, K48-ubiquitination of TRAF3 by cIAP1/2 leads to auto-inactivation of the complex and stabilization of cytosolic NIK (58). NIK in turn phosphorylates IKKα, which activates p100 and leads to its partial proteasomal processing to p52. The p52:RelB dimer is then released for nuclear translocation and gene transactivation (Figure 3). TWEAK signaling subsequently triggers the degradation of TRAF2, TRAF3, and cIAP1/2 through both proteasomal and lysosomal pathways (17, 18, 59, 60). The lysosomal degradation mechanism may represent a separate mode of NF-κB activation unique to TWEAK, since inhibiting lysosomal protein degradation is sufficient to completely prevent p100 processing (18). Unlike the stimulation of the canonical pathway, which is quite rapid, the non-canonical pathway is gradually activated over several hours, possibly due to the requirement for de novo NIK translation and accumulation. The lysosomal degradation of cIAP1 and TRAF2 by TWEAK impairs NF-κB activation. However, membrane-bound TWEAK is highly capable of activating canonical NF-κB signaling (47), as described in the next section. Remarkably, these negative consequences of TWEAK signaling are also seen upon Fn14 upregulation due to stress or injury, even when TWEAK levels remain unchanged. This is due to the greater chance for receptor oligomerization and clustering to occur, which is needed to induce downstream signaling events (50).

During myogenesis, canonical NF-κB activity promotes myoblast proliferation and inhibits differentiation [reviewed elsewhere (51–53), and see Figures 1 and 4 for illustration]. These effects are important during the early phases of muscle regeneration, where efficient repair necessitates rapid expansion of the myoblast population. Notably, following muscle damage, the first wave of inflammatory cells release a plethora of inflammatory cytokines, such as TNFα, IL-6, and TWEAK, which are potent activators of NF-κB signaling (54, 55). During chronic regenerative cycles observed in certain muscle disorders, such as Duchenne muscular dystrophy, the continued presence of such inflammatory cytokines both impairs muscle repair and aggravates the resulting pathology (56). This differential effect of transient and chronic cytokine signaling will be discussed later in this review, in the context of non-myogenic contributors to myogenesis.
FIGURE 2 | cIAP1/2 regulation of TNFα-induced canonical NF-κB pathway activation and suppression of default death pathways.

(A) The E3 ubiquitin ligases cIAP1 and cIAP2 are required for TNFα activation of canonical NF-κB signaling, and to suppress TNFα-induced caspase-8 death pathway. These two cIAPs are recruited to the TNFα receptor, TNFR1, via their association with the adaptor protein TRAF2. Upon ligand stimulation, the cIAPs promote K63-linked polyubiquitination of RIP1, which creates a signaling scaffold (or signalosome complex) to recruit the TAK1 kinase, LUBAC, otherwise known as the linear ubiquitin chain assembly complex (consisting of Sharpin, HOIL-1L, and HOIP), and the trimeric IKK kinase complex (consisting of IKKα, IKKβ, and IKKγ/NEMO). This signalosome formation results in the activation of the IKK complex, and subsequent phosphorylation and degradation of the NF-κB inhibitor, IκB, which occurs within minutes. This allows canonical NF-κB heterodimers to form and translocate into the nucleus to alter gene expression profiles over several hours, which affects many pathways such as survival, proliferation, inflammation, muscle atrophy, and NF-κB signaling itself. This pathway is subject to negative regulation by the deubiquitinase, A20, for example.

(B) In the absence of the cIAPs, the unmodified RIP1 can form a death complex with FADD and caspase-8 known as the ripoptosome. This apoptotic death pathway can also default to a necrotic-like pathway in the absence of caspase-8, through another complex called the necrosome which involves the kinases RIP1 and RIP3, mixed lineage kinase domain-like (MLKL) and the short and long forms of the phosphatase PGAM5.

by other cytokines that require these adaptors; thus, TWEAK sensitizes cancer cells to TNFα-induced apoptosis through activation of caspase-8 (8, 18, 61). The cIAPs are thus considered to be negative regulators of the non-canonical NF-κB pathway, through their constitutive effects on NIK degradation. The binding of TWEAK to Fn14 then relieves this cIAP1/2 suppression by recruiting the TRAFs and cIAPs to the receptor, away from NIK. This membrane receptor sequestration of the cIAPs and TRAFs may be sufficient for NIK stabilization, or may require further degradation and loss of those factors to fully activate NIK as illustrated in Figure 3.

TWEAK AND cIAP1 AS REGULATORS OF MYOBLAST FUSION

While the functions of canonical NF-κB signaling in muscle regeneration and atrophy have been investigated extensively over the years (52, 62, 63), very few studies have examined the role of non-canonical NF-κB in skeletal muscle. In 2001, a paper (64) suggested that NIK and IKKα promote differentiation of the rat L6E9 myoblast cell line. More recently, the non-canonical NF-κB signaling was implicated in muscle resistance to metabolic stress (65), and as a factor specifying the oxidative mode of glucose metabolism in muscle fibers (66). We had observed that primary myoblasts from cIAP1−/− mice [note that skeletal muscle does not express cIAP2 (28)] exhibit constitutively elevated canonical and non-canonical NF-κB activity. We reasoned that upon differentiation of cIAP1−/− myoblasts into myotubes, which are the in vitro analogs of muscle fibers, both canonical and non-canonical NF-κB pathways should produce separate respective phenotypes.

The initial outcome of our experiments was unexpected. While there was a clear delay in cell cycle exit and differentiation of cIAP1−/− myoblasts, the resulting myotubes were characterized by significant hypernucleation and increased myotube size, indicative of a robust fusion response. Subsequent experiments showed...
At low concentrations, exogenous TWEAK led to robust activation in vitro to the same robust extent observed that the elevated non-canonical NF-κB activity, resulting from the loss of cIAP1, was responsible for this effect (17). This observation highlighted a disparity between immortalized myoblast cell lines (C2C12) and primary myoblasts. In C2C12 cells, p100 processing to p52 increases over the time course of differentiation (65). In contrast, primary cells exhibit the greatest p100 processing at the myoblast stage; processing diminishes markedly as muscle fibers form (17). The increased myoblast fusion observed in cIAP1−/− cells could be recapitulated using low doses of TWEAK. At low concentrations, exogenous TWEAK led to robust activation of the non-canonical NF-κB pathway. At higher concentrations, TWEAK activated both canonical and non-canonical pathways. The requirement for high TWEAK concentrations to activate canonical NF-κB suggests that this pathway represents a secondary mode of signaling for TWEAK. In order to further investigate the physiological consequences or TWEAK activity in vivo, we employed the snake venom cardiotoxin (CTX) model of muscle injury, which involves the direct injection of CTX into muscle. This treatment causes rapid development of focal necrotic lesions, but also initiates a robust regenerative response. Following CTX injection, the cIAP1−/− muscle exhibits a slight increase in average muscle fiber size as compared to wildtype controls, but not to the same robust extent observed in vitro (17). This is likely an outcome of the interplay and functional antagonism between both NF-κB pathways. TWEAK administered by micro-osmotic pump produced greater increases in fiber size than did the loss of cIAP1, further indicating the preference of TWEAK for non-canonical NF-κB signaling. In regenerating muscle, the window of regenerative opportunity is very narrow; the majority of myogenesis occurs within 4 days of the injury. A delay in the development of fusion competence – as can be caused by elevated canonical NF-κB activity – may be sufficient to reduce the muscle’s regenerative potential. Collectively, the data indicate that enhanced myogenesis is best achieved by attenuating the canonical NF-κB pathway, and promoting fusion through the non-canonical corollary [(17); see also Figure 4].

The evidence to date shows that both canonical and non-canonical NF-κB pathways are concurrently active in proliferating and differentiating mouse myoblasts. During the process of muscle differentiation, both pathways are similarly inactivated. However, these NF-κB pathways clearly have complementary but opposing functions in muscle regeneration (Figures 1 and 4). While the canonical pathway is important during myoblast proliferation (67), the reported effects of non-canonical NF-κB signaling on stress resistance (65), metabolism (66), and fusion (17) are all features specific to developing muscle fibers, rather than to myoblasts. Therefore, a model can be proposed in which canonical NF-κB activity is switched off to suppress myoblast proliferation thereby allowing for their differentiation. At this point, non-canonical NF-κB predominates, likely driven by TWEAK stimulation, to promote

![Figure 3](https://www.frontiersin.org)
Knockout studies have revealed disparities between the muscle-intrinsic effects of TWEAK and Fn14 on regeneration. Upon muscle injury, TWEAK−/− mice exhibit more rapid muscle regeneration than wildtype controls; in contrast, mice over-expressing TWEAK under a muscle-specific promoter exhibit slower regeneration (71). However, TWEAK is not normally expressed in myoblasts either in vivo or in vitro (15, 17), suggesting that the phenotype observed in the knockout mice may result from decreased paracrine signaling from other TWEAK-producing cells such as macrophages. Fn14 expression in muscle is clearly induced during regeneration and atrophy (16, 50), and mice lacking Fn14 exhibit considerably impaired regeneration. This effect can be recapitulated in vitro in the absence of TWEAK (16, 17), highlighting the possibility that Fn14 may play essential roles independent of TWEAK.

The application of TWEAK/Fn14 therapeutics in the context of muscle regeneration may at first appear somewhat counterintuitive, until the specific mechanistic intent is examined closely, and hypotheses are tested. Most of the published reports on TWEAK highlight its aggravating role in muscle (72, 73), liver (74), kidney (75) and neurological (76) regeneration or repair. A consistent feature of these studies however, is the pathologically elevated levels of TWEAK signaling, due either to the experimental intervention (transgenic over-expression of TWEAK) or a chronic, localized over-production of cytokine (77). However, we propose that transient TWEAK/Fn14 activation at physiological levels may prove beneficial (Figure 5). Consistent with this idea, a number of studies have shown that TWEAK can act as a mitogen to stimulate proliferation of progenitor cells (15, 78–81). In particular, soluble TWEAK, particularly at low concentrations, preferentially activates the non-canonical NF-κB pathway, whereas high concentrations are sufficient to mobilize both canonical and non-canonical pathways (17, 48). Therapeutic activation of the non-canonical pathway has been suggested in a number of separate contexts. For example, TWEAK promotes lymphocyte and T cell recruitment to the kidney following renal injury by inducing expression of the chemokine CCL21 in a non-canonical NF-κB-specific manner (82, 83). TWEAK is also important to prevent certain lymphoproliferative disorders that lead to impaired antibody responses (84, 85). A better understanding of the mechanisms of TWEAK signaling should permit an informed tailoring of its uses, such as with agonistic and antagonistic antibodies (48), for particular therapeutic applications.

### NF-κB, NFAT SIGNALING, AND THE PROMOTION OF MYOBLAST FUSION

Extracellular calcium is one of the earliest known regulators of myoblast fusion. In 1969, Shainberg and colleagues (86) demonstrated that fusion of chick myoblasts could be reversibly blocked by removing Ca\(^{2+}\) ions from the growth medium. These results were confirmed in multiple species (87–89). Importantly, it was shown that extracellular calcium is not required for myoblast cell cycle exit or for muscle-specific gene expression (90–93). Calcium was subsequently identified as a potent activator of the nuclear factor of activated T cells (NFAT) transcription factor pathway. Out of five proteins in this family, three – NFAT-c1, -c2, and -c3 – are regulated by calcium and expressed in skeletal...
FIGURE 5 | Differential activation of NF-κB pathways by TWEAK based on strength of Fn14 signaling. TWEAK can signal either in a juxtacrine manner, as a membrane-bound ligand, mTWEAK (A), or in a paracrine manner as a soluble ligand, sTWEAK (B,C). Depending on the concentration of ligand or receptor, or the propensity of the Fn14 ligand to oligomerize the receptor and form signaling clusters, differential activation of the NF-κB pathways occurs. (A) During juxtacrine signaling, mTWEAK favors the clustering of Fn14 on the opposite cell, leading to hyperactive signaling for which canonical NF-κB signaling predominates over non-canonical signaling. MAPK activation also occurs. (B) Under physiological conditions, low endogenous levels of sTWEAK signal in a paracrine manner, leading predominantly to non-canonical NF-κB activation. (C) However, under certain pathological or experimental conditions, sTWEAK can also lead to hyperactive signaling leading to canonical NF-κB and MAPK signaling. For example, high concentrations of TWEAK, applied to myoblasts or myotubes ex vivo, hinder differentiation and cause atrophy, respectively. Transgenic over-expression of TWEAK in mice also leads to pathological consequences. In a variety of injury states (such as denervation-induced muscle atrophy), the receptor Fn14 is induced, which then is followed by and pathological responses to endogenous levels of TWEAK. Furthermore, recombinant TWEAK fusion proteins with the ability to multimerize, or Fn14 agonistic antibodies, can both promote receptor clustering and the activation of the canonical NF-κB pathway. The pathways leading to pathological activation of the canonical NF-κB pathway are still poorly defined, but are thought to arise either from pathway cross-talk, such as that seen with NIK or IKK activation of the canonical mediators, or through the adaptor and E3 ubiquitin ligase TRAF6. In addition, activation of MAPK pathways may also contribute to the pathology observed.

Evidence from some published reports suggest that the TWEAK/Fn14/cIAP signaling axis may act through one or more NFAT pathways to regulate myoblast fusion. Upon inactivation of the non-canonical NF-κB pathway in wildtype myoblasts, myotubes still form, but are small and have reduced numbers of nuclei (17). This phenotype is similar to that observed with NFATc2−/− cells (99), where myogenesis stalls at the primary myotube phase. The existence of cross-talk between the structurally similar NFAT and NF-κB transcription factors is well-established (100–102). A recent study indicated that RANKL, which like TWEAK activates both canonical and non-canonical NF-κB pathways in osteoclasts, induces expression of NFATc1 in a manner that requires NIK (103), suggesting that NFATc1 may be a target of the non-canonical pathway. Furthermore, cIAP1/2 was shown to suppress NFATc1 expression in response to RANKL; conversely, loss of cIAP1/2 led to upregulation of NFATc1 in osteoclasts (104).

Our understanding of molecular triggers and signaling pathways that are critical to myoblast fusion is still very limited. While the list of known effectors of fusion is extensive [as has been categorized in other recent reviews (105, 106)], a coherent picture of timing, mechanism, and relative importance has yet to emerge. It

muscle (93). Ca2+ -activation of the phosphatase calcineurin leads to the dephosphorylation of NFAT proteins. These then translocate to the nucleus where they activate the transcription of a range of NFAT target genes (94). Multiple stimuli that potentiate the Ca2+ -calcineurin-NFAT signaling axis, such as calcium ionophores (95), increase myoblast fusion; conversely, substances that deplete intracellular or extracellular calcium stores, such as EDTA and thapsigargin, impair myoblast fusion (96, 97). A notable aspect of NFAT transcription factors is that they mediate different aspects of myoblast fusion. Whereas NFATc3 is calcium-responsive in myoblasts, NFATc1 and NFATc2 are active in nascent myotubes (93). This suggests that they differentially regulate primary fusion (myoblast–myoblast) and secondary (myoblast–myotube) fusion events (Figure 1). Consistent with this hypothesis, the protein four-and-a-half LIM 1 (FHL1) is a co-factor of NFATc1; over-expression of FHL1 increases myoblast fusion in vitro and in vivo (98). Muscle fiber formation is also impaired in NFATc2−/− mice (99). Collectively the data indicate a hierarchical process of fusion, whereby primary myotubes, formed under control of NFATc3, recruit further myoblasts in an NFATc1- or NFATc3-specific manner for formation of secondary myotubes and continued myogenesis.
seems likely that the TWEAK-NF-κB signaling axis converges with the transcriptional upregulation of one or more muscle-derived cytokines or chemokines (referred to as “myokines”). A search for known targets of the non-canonical NF-κB pathway, including such molecules as CCL19 and CCL21 (83), should provide further insight into the placement of NF-κB within the stepwise processes of fusion.

INNATE IMMUNITY AND MUSCLE REGENERATION MEDIATED BY THE CYTOKINES IL-4, IL-10, AND IL-13

In the context of regenerating muscle, a number of recent papers have examined the interplay between muscle cells and multiple non-muscle lineages that participate in the regenerative process. Following muscle injury, an inflammatory response emerges, which involves the infiltration of myeloid cell types such as eosinophils, basophils, mast cells, macrophages, and leukocytes (107, 108). These cells release a medley of cytokines and chemokines; the leukocytes in particular are robust sources of inflammatory cytokines such as IL-6, TNFα-dominated by CD68-expressing “M1” macrophages, produce pro-inflammatory cytokines such as IL-6, TNFα, and IL-1β (54). The timing of M1 influx correlates with the activation of satellite cells and proliferation of myoblasts, a process that is enhanced by canonical NF-κB activation. The M1 macrophages are subsequently replaced with CD163-expressing “M2” macrophages, which promote muscle growth through the secretion of IL-4, IL-10, and IL-13. The M2 response occurs during the phase of muscle regeneration predominated by myoblast fusion, which may be enhanced by M2-derived cytokines such as IL-4 and IL-13.

The various contributions of inflammatory and lymphoid cells to the course of muscle regeneration have been assessed in injury models. A commonly used animal model of muscle injury is the mdx mouse, which exhibits many of the hallmark symptoms and pathology of the human disorder known as Duchenne muscular dystrophy. In mice and humans, the disease results from loss of the structural protein dystrophin, which leads to increased muscle fragility and continued cycles of injury and regeneration (111). This creates a chronic inflammatory milieu in muscle, which both aggravates and perpetuates the pathology. In mdx mice depleting of macrophages during the early stages of the disease, muscle injury is significantly reduced (112). Similar outcomes are observed in mdx mice depleted of CD8-positive cytotoxic T cells alone (113), or of both CD4-positive helper and CD8-positive T cell populations (114). An important point of note, however, is that these studies describe the outcome of short-term depletion of these cell populations on the dystrophic phenotype. In an analysis of mdx mice crossed with scid mice (lacking both mature T and B cells), no differences in muscle fiber size, percentage of regenerated fibers, or muscle force were observed as compared to immunocompetent mdx mice (115). In contrast, mice depleted of monocytes and macrophages, using a targeted cytotoxic diphtheria toxin approach, exhibit severely impaired muscle regeneration (116). These observations are consistent with the biphasic and important roles of M1 and M2 macrophages in the regenerative process.

Also relevant to this stage of regeneration is a recently identified population of fibro/adipogenic progenitors (FAPs), which are essential contributors to normal muscle regeneration following acute trauma (117–122). These FAPs, like satellite cells, are activated following muscle injury, and proliferate in response to IL-4 and IL-13 secreted by eosinophils (123). IL-4 also specifies the fate of FAPs as phagocytes rather than fat-generating adipocytes. In the absence of IL-4/IL-13-secreting eosinophils or in an IL-4 receptor α-knockout (IL-4Rα−/−) background, muscle regeneration is severely impaired, at least in part due to excessive deposition of FAP-generated brown fat. There are currently no studies explicitly examining the relationship between TWEAK and FAPs during myogenesis; nevertheless corollary evidence from other tissue systems suggests that TWEAK may promote muscle regeneration through regulation of FAP differentiation. TWEAK and Fn14 are expressed in adipocytes (124, 125), and TWEAK inhibits adipocyte differentiation (126). This occurs at least in part through the blunting of pro-inflammatory and pro-adipogenic signaling induced through the canonical NF-κB pathway by TNFα (125–127). Still further, TWEAK synergizes with IL-13 as a fibrolblast mitogen (127, 128). Given the overlap between the influx of TWEAK-expressing M2 macrophages and FAP activation during regeneration, it seems likely that the pro-regenerative context established by both cell types may involve low levels of secreted TWEAK as a paracrine regulator of muscle regeneration.

Given the upregulation of Fn14 following muscle injury, and the influx of TWEAK-expressing myeloid cells, it is likely that the non-canonical NF-κB signaling has a direct influence on the course of muscle repair. The highly orchestrated nature of the innate immune response in damaged muscle, which occurs in synchrony with the course of muscle differentiation and fusion, is critical to normal muscle regeneration. This timing is controlled by IL-10 (129), which deactivates M1 macrophages; and by AMPKα1, which is required for macrophage acquisition of an M2 phenotype (130). Given that such timing is disrupted in chronic degenerative muscle diseases and myopathies, factors that skew the population distribution in favor of an M2 phenotype may improve muscle regeneration in disease conditions. This hypothesis is supported by certain acute experiments in which administration of exogenous IL-4 (123) or IL-10 (131) was found to promote necrotic cell clearance and muscle regrowth.

Recently we evaluated the effect of cIAP1 loss on muscle function in the mdx mouse model of Duchenne muscular dystrophy (132). In cIAP1−/− mice double-mutant mices, muscle regeneration was attenuated in some muscle groups, particularly the soleus and diaphragm. The outcome was that double-mutant mice exhibited improved muscle resiliency and exercise endurance as compared to the mdx controls. These results were accompanied by a reduction in pro-inflammatory M1 macrophages, and an increase in pro-regenerative M2 macrophages in muscle tissue. These results suggest that non-canonical NF-κB activation, through loss of cIAP1 can mediate diverse effects that converge to improve muscle regeneration and function. It remains to be seen if low doses of TWEAK, which would more specifically target the non-canonical pathway, can recapitulate these positive effects on muscle regeneration.
TWEAK SIGNALING IN DIABETES AND MUSCLE REGENERATION
Skeletal muscle is responsible for the uptake of 80% of blood glucose (133–135); consequently, the outcome of prolonged insulin resistance in muscle is primarily type 2 diabetes (136). The presence of excessive fat deposits is associated with both onset and progression of type 2 diabetes (137). It was recently discovered that high-glucose diets trigger the differentiation of multipotent myoblasts into adipocytes (138). While the resulting fat deposits can accelerate insulin resistance through autocrine release of TNFα, TWEAK can inhibit this process by blocking TNF-mediated activation of JNK (139). TWEAK is constitutively expressed in adipose tissue (124, 125), suggesting that it actively antagonizes the process of insulin resistance. Evidence for this is shown by a recent study demonstrating that reduced levels of TWEAK correlate with increased risk of diabetes (140), at least in part by reducing autocrine release of TNFα from adipocytes (141). Overall, these findings suggest that TWEAK can operate in a feed-forward mechanism to both promote muscle regeneration and attenuate the pathogenesis of diabetes.

While TWEAK-expressing adipocytes may be beneficial for the purposes of insulin tolerance, it is naturally preferable to reduce fat deposition in muscle altogether. This is consistent with a beneficial role for FAPs in muscle regeneration when the differentiation choice toward adipocytes is blocked (123, 142, 143). Remarkably, TWEAK is a potent inhibitor of adipocyte differentiation and functions, unlike TNFα, without affecting glucose uptake or cytokine release (126). Collectively, the data show that TWEAK signaling can positively regulate homeostasis by improving glucose tolerance in muscle, reducing fat deposition, and reducing adipocyte differentiation of FAP cells during muscle regeneration.

CONCLUSION
The array of recent discoveries on the functions and mechanisms of action of TWEAK offer several intriguing possibilities into both the frontiers of new biology and the potential for therapeutic interventions. The ability of TWEAK/Fn14 to preferentially activate the non-canonical over the canonical NF-κB pathway (17) places TWEAK in a category of TNF superfamily members along with BAFF, CD40L, RANKL, and lymphotoxins β (144). This implicts TWEAK in immunological functions that have, to date, been explored only briefly. The preferential activation of the canonical pathway by membrane-bound TWEAK and the upregulation of Fn14 upon injury are likely the causes of most TWEAK-associated pathology (47, 50). Thus, the paradox of TWEAK as a beneficial and deleterious cytokine becomes a matter of degree; whereas low concentrations of soluble TWEAK can be beneficial for immunological and regenerative purposes, high levels of TWEAK or Fn14 may have pathological consequences, and require intervention using neutralizing antibodies or TWEAK inhibitors.

ACKNOWLEDGMENTS
Research funding to Robert G. Korneluk is provided by the Canadian Institutes of Health Research and the Muscular Dystrophy Association (USA).

REFERENCES
1. Yin H, Price F, Budnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev (2013) 93(1):23–67. doi:10.1152/physrev.00043.2011
2. Birbrair A, Zhang T, Wang ZM, Messi ML, Enikolopov GN, Mintz A, et al. Role of pericytes in skeletal muscle regeneration and fat accumulation. Stem Cells Dev (2013) 22(16):2298–314. doi:10.1089/scd.2012.0647
3. Sato S, Ogura Y, Kumar A. TWEAK/Fn14 signaling axis mediates skeletal muscle atrophy and metabolic dysfunction. Front Immunol (2014) 5:184. doi:10.3389/fimmu.2014.00108
4. Feng SL, Gao Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate–early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 156(4):1253–61. doi:10.1016/S0002-9440(00)64996-6
5. Wiley SR, Cassiano J, Lofton T, Darris-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 15(5):837–46. doi:10.1016/S1074-7613(01)00223-1
6. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, SF, Pleitgen KA, et al. The mitogen-inducible Fn14 gene encodes a type 1 transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem (1999) 274(46):33166–76. doi:10.1074/jbc.274.46.33166
7. Brown SA, Richards CM, Hanscom HM, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation. Biochem J (2003) 371(Pt 2):395–403. doi:10.1042/BJ20021730
8. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, et al. TNF-like weak inducer of apoptosis inhibits proinflam-atory TNF receptor-1 signaling. Cell Death Differ (2009) 16(1):1445–59. doi:10.1038/cdd.2009.80
9. Burdick LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunolog-ical switch for shaping tissue responses. ImmunoL Rev (2011) 244(1):99–114. doi:10.1111/j.1600-065X.2011.01054.x
10. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interac-tions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem (2008) 283(20):13964–71. doi:10.1074/jbc.M800276200
11. Bower LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previ-ous unrecognized protein–protein interaction between TNF and CD163: potential biological implications. J Immunol (2007) 178(12):8183–94.
12. Polek TC, Talpar M, Darnay BG, Spiwa-Kroizman T. TWEAK mediates sig-nal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem (2003) 278(34):32317–23. doi:10.1074/jbc.M302518200
13. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, et al. Development and characterization of a potent immunocconjugate target-ing the Fn14 receptor on solid tumor cells. Mol Cancer Ther (2011) 10(7):1276–88. doi:10.1158/1535-7163.MCT-11-0161
14. Brown SA, Cheng E, Williams MS, Winkles JA. TWEAK-independent Fn14 self-association and NF-kappaB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PloS One (2013) 8(6):e65248. doi:10.1371/journal.pone.0065248
15. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progen-itor cells and skeletal muscle regeneration. EMBO J (2006) 25(24):5826–39. doi:10.1038/sj.emboj.7601441
16. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A. Fibroblast growth fac-tor inducible 14 (Fn14) is required for the expression of myogenic regula-tory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J Biol Chem (2007) 282(20):15000–10. doi:10.1074/jbc.M608666280
17. Enwere EK, Holbrook J, Lejmi-Mrzd R, Vineham J, Timusk K, Sivaraj B, et al. TWEAK-Fn14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNF alpha. J Cell Biol (2008) 182(1):171–84. doi:10.1083/jcb.200801101
18. Vazifolooner E, Goncharov T, Maeker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappal and
MAPK activation by members of the TNF family of receptors. Sci Signal (2012) 5(240):ra22. doi:10.1126/scisignal.2001878

20. Oh H, Ghosh S. NF-kappaB: roles and regulation in different CD4+ T-cell subsets. ImmunoL Rev (2013) 252:141–51. doi:10.1111/imr.12033

21. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell (1995) 83(7):1243–52. doi:10.1016/0092-8674(95)90149-3

22. Shu HB, Takemichi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A (1996) 93(24):13973–8. doi:10.1073/pnas.93.24.13973.5

23. Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. Cloning and expression of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell (2008) 30(4):24295–9. doi:10.1016/j.molcel.2010.09.008

24. Vincent JE, Wong WY, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cytopathic death by inducing apoptosis. Nat Immunol (2008) 9(11):1166–73. doi:10.1038/ni.1676

25. Liston P, Roy N, Tamai K, Lehtovaara M, Surin CD, et al. NF-kappaB activation: a tale of two pathways in skeletal myogenesis. J Cell Biol (2010) 188(6):833–49. doi:10.1083/jcb.201006.006

26. Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, et al. A novel c-IAP1 in vivo. J Mol Med (2010) 88(10):4974–8. doi:10.1038/sj.jem.1803490

27. Bertoncello I, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg H, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 10(11):1309–17. doi:10.1038/ncb1789

28. Gonzalez RR, Albert L, Ferrick DA, Goeddel DV, Yeh WC, Mak T, et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol (2005) 25(8):3348–56. doi:10.1128/MCB.25.8.3348-3356.2005

29. Schoemaker MH, Ros JE, Homan M, Trautwein C, Liston P, Poelstra K, et al. Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. J Hepatol (2002) 36(6):742–50. doi:10.1016/S0168-8278(02)00063-6

30. Missetsides CS, Missetsides N, Poulaki V, Schlossmann R, Akiyama M, Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cell: therapeutic implications. Oncogene (2002) 21(37):5673–83. doi:10.1038/sj.onc.1205664

31. Xiao Z, Laver T, Hong SW, Twitty GB Jr, Devos A, Devos M, et al. An NF-kappaB p65-cIAP2 link is necessary for mediating resistance to TNF-alpha induced cell death in gliomas. J Neurooncol (2011) 102(3):367–81. doi:10.1007/s11060-010-0346-y

32. Dynek IN, Goncharov T, Dueber EC, Fedorova AV, Israel-Tomasevic A, Phu L, et al. c-IAP1 and UbeH5 promote K11-linked polyubiquitination of RIP1 in TNF signaling. EMBO J (2010) 29(24):4198–209. doi:10.1038/emboj.2010.300

33. Tener T, Bianchi K, Darding M, Broemmer M, Langscheid C, Wallberg F, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell (2011) 43(3):442–48. doi:10.1016/j.molcel.2011.06.011

34. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol (2010) 56:349–53. doi:10.1152/ajpregu.00735.2009

35. Bakkar N, Moshir M, Salzmann S, Moshir M, Silence K, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cell: therapeutic implications. Mol Cell Biol (2008) 28(12):3793–801. doi:10.1128/MCB.25.12.3793-3801.2005

36. Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. Mol Med (2011) 17:297–308. doi:10.4161/mabs.26709

37. Tidball JG, Bhatnagar S, Kumar A, Lach-Triffiliev E, Wauters S, Li H, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol (2010) 188(6):683–9. doi:10.1083/jcb.200909117

38. Meurkens J, Rosenthal N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med (2008) 86(7):747–59. doi:10.1007/s00109-008-0308-4

39. Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev (2010) 90(2):495–511. doi:10.1152/physrev.00040.2009

40. Peterson JM, Bakkar N, Guttridge DC. NF-kappaB signaling in skeletal muscle health and disease.Curr Top Dev Biol (2011) 96:85–119. doi:10.1016/B978-0-12-385940-2.00004-8

41. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol (2010) 298(5):R1173–87. doi:10.1152/ajpregu.00755.2009

42. Merritt EK, Thalacker-McFerrin CA, Cross GM, Windham ST, Thomas SJ, Barm man MM. Increased expression of atrogens and TWEAK family members after severe burn injury in nonburned human skeletal muscle. J Burn Care Res (2013) 34(5):e297–304. doi:10.1097/BCR.0b013e31827a29ac

43. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol (2005) 288(2):R345–53. doi:10.1152/ajpregu.00454.2004
57. Vallabhappurapu S, Matsurawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 9(12):1364–70. doi:10.1038/ni.1678

58. Liao G, Zhang M, Harhay EW, Sun SC. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem (2004) 279(25):26243–50. doi:10.1074/jbc.M403286200

59. Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem (2010) 285(23):17525–36. doi:10.1074/jbc.M109.087635

60. Dardling M, Feltham R, Tenev T, Bianchi K, Betanotos C, Silke J, et al. Molecular determinants of smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ (2011) 18(8):1376–86. doi:10.1038/cdd.2011.10

61. Salzmann S, Lang I, Rosenthal A, Schröter A, Weisenberger D, Carmona Arana JA, et al. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes. J Immunol (2013) 191(5):2308–18. doi:10.4049/jimmunol.1202899

62. Tisdale ME. Mechanisms of cancer cachexia. Physiol Rev (2009) 89(2):381–410. doi:10.1152/physrev.00016.2008

63. Jackman BW, Cornwell EW, Wu CL, Kandarian SC. Nuclear factor-kappaB signaling and transcriptional regulation in skeletal muscle atrophy. Exp Physiol (2013) 98(1):19–24. doi:10.1113/expphysiol.2011.063321

64. Canicino J, Ruiz-Lozano P, Carrasco M, Palacin M, Chien K, Zorrano A, et al. Nuclear factor kappa B-inducing kinase and Ikkappa B-kinase-alpha skeletal muscle cell differentiation. J Biol Chem (2001) 276(22):20228–33. doi:10.1074/jbc.M107182000

65. Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, et al. Ikk/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Biol Chem (2008) 283(4):787–802. doi:10.1074/jbc.M70277179

66. Bakkar N, Ladner K, Canan BD, Lyanarachchi S, Bal NC, Pant M, et al. Ikk alpha and alternative NF-kappaB regulate Pgc-1beta to promote oxidative muscle metabolism. J Biol Chem (2012) 196(4):497–511. doi:10.1074/jbc.M111088118

67. He WA, Berardi E, Cardillo VM, Achariya S, Aulino P, Thomas-Ahner J, et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest (2013) 123(11):4821–32. doi:10.1172/JCI62653

68. Shembade N, Ma A, Harhay EW. Inhibition of NF-kappaB signaling by ATOH2 through disruption of ubiquitin enzyme complexes. Science (2010) 327(5969):1155–9. doi:10.1126/science.1182364

69. Yamaguchi N, Oyama M, Kozuka-Hata H, Inoue J. Involvement of A20 in apoptosis-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, apoptosis, and tissue homeostasis. J Immunol (2002) 169(9):4301–7.

70. Schollmeyer JE. Role of Ca2+ and Ca2+-activated protease in myoblast fusion. J Cell Differ (1976) 5:230–4. doi:10.1007/BF0021671-X

71. Yaffe D. Developmental changes preceding cell fusion during muscle differentiation in vitro. Exp Cell Res (1971) 66(1):33–48. doi:10.1016/0014-4827(71)90008-3

72. Cox PG, Gun M. The effect of calcium ion concentration on myoblast fusion in vitro. Exp Cell Res (1973) 79(1):169–78. doi:10.1016/0014-4827(73)90528-8

73. Persnson BH, Strohman RC. Myosin synthesis in cultures of differentiating chicken embryo skeletal muscle. Dev Biol (1972) 29(2):113–8. doi:10.1016/0012-1606(72)90050-4

74. Adams S, Zani B, Sarucasa G, Molinario M. Expression of differentiative traits in the absence of cell fusion during myogenesis in culture. Cell Differ (1976) 5(1):53–67. doi:10.1006/cell.1976.10015

75. Vases MS, Konigbresk I. Maintenance of proliferative capacity during avian myogenesis is independent of fusion-permissive calcium ion concentration. Exp Cell Res (1985) 158(1):360–70. doi:10.1016/0014-4827(85)90461-6

76. Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. Activation and cell-cell signaling pathways. Am J Pathol (2005) 165(1):921–9. doi:10.1139/H07-093

77. Schollmeyer JE. Role of Ca2+ and Ca2+-activated protease in myoblast fusion. Exp Cell Res (1986) 162(2):411–22. doi:10.1016/0014-4827(86)90364-0

78. Paterson B, Strohman RC. Calcium-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab (2007) 32(5):921–9. doi:10.1139/H07-093

79. Lee KH, Park JY, Kim K. NMDA receptor-mediated calcium influx plays an essential role in myoblast fusion. FEBS Lett (2004) 578(1–2):47–52. doi:10.1016/j.febslet.2004.10.076
Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in muscular dystrophy. *FASEB J* (2007) 21(11):2994–3003. doi:10.1096/j.0006-4409.com

Cowling BS, McGrath MJ, Nguyen MA, D’Antona G, et al. Identification of FHL1 as a regulator of skeletal muscle mass involvement in human hypomyopathy. *J Cell Biol* (2008) 183(6):1033–48. doi:10.1083/jcb.200804077

Horsley V, Jansen KM, Mills ST, Pavlath GK. IL-4 as a acts as a myoblast recruiting factor during mammalian muscle growth. *Cell* (2003) 113(4):483–94. doi:10.1016/S0092-8674(03)00319-2

Serfling E, Berberich-Siebelt F, Avots A, Chuvpilo S, Klein-Hessling S, Jha MK, et al. NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in cells. *Curr Cancer Drug Targets* (2011) 11(5):548–59. doi:10.2174/1389103911310070002

Li Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NFkappaB and NFAT in the context of cardiac hypertrophy and pathological remodeling. *Circ Res* (2012) 110(8):1077–86. doi:10.1161/CIRCRESAHA.111.260729

Maruyama T, Fukushima H, Nakao K, Shin M, Yasuda H, Weih E, et al. Processing of the NF-kappaB B2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation. *J Bone Miner Res* (2010) 25(5):1058–67. doi:10.1359/jbmr.091102

Yamaguchi N, Yokota M, Taguchi Y, Gohda J, Inoue J, cIAP1/2 negatively regulate RANKL-induced osteoclastogenesis through the inhibition of NFATc1 expression. *Genes Cells* (2012) 17(1):97–81. doi:10.1111/j.1468-1354.2012.01120.x

Abnáey SM, Pavlath GK. Myoblast fusion: lessons from fibres and mice. *Development* (2012) 139(19):461–56. doi:10.1242/dev.068533

Hindi SM, Tajrishi MM, Kumar A. Signaling mechanisms in mammalian muscle fibers. *Mucosal Immunol* (2013) 6(6):1033–48. doi:10.1038/mi.2013.12

Marino M, Scuderi F, Provenzano C, Bartoccioni E. Skeletal muscle cells: from local inflammatory response to active immunity. *Gene Ther* (2011) 18(2):109–16. doi:10.1038/gt.2010.124

Milner DJ, Cameron JA. Muscle repair and regeneration: stem cells, scaffolds, and the contributions of the skeletal muscle to amphibian limb regeneration. *Curr Top Microbiol Immunol* (2013) 367:133–59. doi:10.1007/82_2012_292

Kataria NG, Bartold PM, Dharmapatni AA, Atkins GJ, Holding CA, Haynes DR. Inflammatory monocytes recruited after skeletal muscle injury switch into active immunity. *J Clin Invest* (1997) 99(11):2745–51. doi:10.1172/JCI1946

Spencer MJ, Montecino-Rodriguez E, Dorskind K, Tidball JG, Helper (CD4(+)c and cytotoxic (CD8(+)c). T cells promote the pathologies of dystrophic skeletal muscle. *Clin Immunol* (2001) 98(2):235–43. doi:10.1006/clim.2000.4966

Farini A, Mereghelli M, Belicchi M, Battistelli M, Parolini D, A. et al. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscle in the scid/mdx mouse. *J Pathol* (2007) 211(3):222–38. doi:10.1002/path.2213

Arnold L, Henry A, Poron F, Baha-Amer Y, van Rooijen N, Plonquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into infiltrating macrophages to support myogenesis. *J Exp Med* (2007) 204(5):1057–69. doi:10.1084/jem.20070075

Joe AW, Yi L, Natarajan A, Le Grand E, So L, Wang J, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. *Nat Cell Biol* (2010) 12(2):153–63. doi:10.1038/nccb2015

Lecourt S, Marolleau JP, Fromigue O, Vacheux K, Andriamanalajoa R, Ternaux B, et al. Characterization of distinct mesenchymal-like cell populations from human skeletal muscle in situ and in vitro. *Exp Cell Res* (2010) 316(15):2513–26. doi:10.1016/j.yexcr.2010.04.020

Uezumii Y, Takeda S, Shimizu S, Yonea T, Segawa M, et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. *J Cell Sci* (2011) 124(21):3654–64. doi:10.1242/jcs.086629

Schulz TJ, Huang TL, Tran TT, Zhang H, Townsend KL, Shadrach R, et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. *Proc Natl Acad Sci U S A* (2011) 108(1):143–8. doi:10.1073/pnas.101929108

Lee YH, Pietkova AP, Mottillo EP, Granneman JG. In vivo identification of bipotential adipocyte progenitors recruited by beta3-adrenergocceptor activation and high-fat feeding. *Cell Metab* (2012) 15(4):480–91. doi:10.1016/j.cmet.2012.03.009

Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. *Cell* (2013) 153(2):376–68. doi:10.1016/j.cell.2013.02.053

Achazi V, Notas G, Plekanová K, Mampa M, Valkanou M, Theodoropoulou P, et al. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. *J Immunol* (2009) 183(9):5948–56. doi:10.4049/jimmunol.0901186

Chacon MR, Richart C, Gomez JM, Mega A, Vilarasana N, Fernandez-Real JM, et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. *Cytochrome* (2006) 33(1):129–37. doi:10.1016/j.cyt.2005.12.005

Tiller G, Fischer-Posovszky P, Laumen H, Finck A, Skurk T, Keuper M, et al. Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. *Endocrinology* (2009) 150(2):5375–83. doi:10.1210/en.2009-0488

Kawashima R, Kawamura YI, Oshio T, Son A, Yamazaki M, Hagiwara T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. *Gastroenterology* (2011) 140(6):2191–e29.e. doi:10.1053/j.gastro.2010.11.040

Son A, Oshio T, Kawamura YI, Hagiwara T, Yamazaki M, Inagaki-Obara K, et al. TWEAK/Fn14 pathway promotes a T helper-2 type chronic colitis with fibrosis in mice. *Mucosal Immunol* (2013) 6(6):1311–21. doi:10.1038/mi.2013.10

Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. *Hum Mol Genet* (2011) 20(4):790–805. doi:10.1093/hmg/ddq523

Mounier R, Théret M, Arnold L, Cuvelier S, Bultot L, Goransson O, et al. AMP-KaP is an ubiquitous regulator of muscle mass. *Cell Metab* (2012) 16(2):251–64. doi:10.1016/j.cmet.2012.06.017

Deng B, Wehling-Henricks M, Villalta SA, Wang Y, Tidball JG. IL-10 triggers changes in macrophage phenotype that promote muscle mass growth and regeneration. *J Immunol* (2012) 189(7):3669–80. doi:10.4049/jimmunol.1103180

Enwere et al. Noncanonical NFκB regulation of myogenesis
Enwere et al. Noncanonical NF-κB regulation of myogenesis

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 November 2013; accepted: 21 January 2014; published online: 05 February 2014.

Citation: Enwere EK, LaCasse EC, Adam NJ and Korneluk RG (2014) Role of the TWEAK-Fn14-cIAP1-NF-κB signaling axis in the regulation of myogenesis and muscle homeostasis. Front. Immunol. 5:34. doi: 10.3389/fimmu.2014.00034

This article was submitted to Inflammation, a section of the journal Frontiers in Immunology.

Copyright © 2014 Enwere, LaCasse, Adam and Korneluk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.